ZMYM6

Summary

ZMYM6 (zinc finger MYM-type containing 6, HGNC:13050) is a protein-coding gene on chromosome 1p34.3, encoding Zinc finger MYM-type protein 6 (O95789). Plays a role in the regulation of cell morphology and cytoskeletal organization.

Predicted to enable DNA binding activity. Involved in cytoskeleton organization and regulation of cell morphogenesis. Predicted to be located in nucleus.

Source: NCBI Gene 9204 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability (Limited, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 170 total
• MANE Select transcript: NM_007167

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13050
Approved symbol	ZMYM6
Name	zinc finger MYM-type containing 6
Location	1p34.3
Locus type	gene with protein product
Status	Approved
Aliases	ZNF198L4, MYM, Buster2, ZBED7, KIAA1353
Ensembl gene	ENSG00000163867
Ensembl biotype	protein_coding
OMIM	613567
Entrez	9204

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 17 protein_coding, 5 protein_coding_CDS_not_defined

ENST00000317538, ENST00000357182, ENST00000373333, ENST00000415531, ENST00000460607, ENST00000466345, ENST00000471566, ENST00000472971, ENST00000493328, ENST00000859302, ENST00000859303, ENST00000859304, ENST00000859305, ENST00000859306, ENST00000929015, ENST00000929016, ENST00000929017, ENST00000929018, ENST00000965365, ENST00000965366, ENST00000965367, ENST00000965368

RefSeq mRNA: 1 — MANE Select: NM_007167 NM_007167

CCDS: CCDS387

Canonical transcript exons

ENST00000357182 — 16 exons

Exon	Start	End
ENSE00001276682	35031815	35031945
ENSE00001409042	34986165	34988935
ENSE00003695435	35005132	35005272
ENSE00003695598	35019353	35019602
ENSE00003695635	35010447	35010597
ENSE00003695850	35020383	35020467
ENSE00003696663	35003968	35004005
ENSE00003696838	35014697	35014888
ENSE00003697227	35008752	35008924
ENSE00003697383	35014988	35015162
ENSE00003697990	35011890	35012005
ENSE00003699132	35010758	35011036
ENSE00003700337	35006951	35007098
ENSE00003700427	35012431	35012581
ENSE00003700713	35030547	35030713
ENSE00003701231	34992234	34992387

Expression profiles

Bgee: expression breadth ubiquitous, 227 present calls, max score 89.35.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.1685 / max 132.9592, expressed in 1794 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
11657	16.1685	1794
11660	7.7752	1716
11661	4.4218	1625
11659	1.1732	658
11656	0.2305	97
11658	0.0327	12

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	89.35	gold quality
adrenal tissue	UBERON:0018303	89.06	gold quality
leukocyte	CL:0000738	88.99	gold quality
calcaneal tendon	UBERON:0003701	86.98	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.99	gold quality
granulocyte	CL:0000094	85.24	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.88	gold quality
mucosa of stomach	UBERON:0001199	83.75	gold quality
left adrenal gland	UBERON:0001234	83.54	gold quality
left adrenal gland cortex	UBERON:0035825	83.54	gold quality
bone marrow cell	CL:0002092	83.52	gold quality
right adrenal gland cortex	UBERON:0035827	83.42	gold quality
rectum	UBERON:0001052	83.20	gold quality
adrenal gland	UBERON:0002369	83.07	gold quality
right adrenal gland	UBERON:0001233	83.03	gold quality
spleen	UBERON:0002106	82.86	gold quality
body of pancreas	UBERON:0001150	82.71	gold quality
metanephros cortex	UBERON:0010533	82.56	gold quality
descending thoracic aorta	UBERON:0002345	82.46	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.24	gold quality
cortical plate	UBERON:0005343	82.23	gold quality
left ovary	UBERON:0002119	82.16	gold quality
adenohypophysis	UBERON:0002196	82.16	gold quality
right ovary	UBERON:0002118	82.08	gold quality
vermiform appendix	UBERON:0001154	82.05	gold quality
smooth muscle tissue	UBERON:0001135	81.76	gold quality
islet of Langerhans	UBERON:0000006	81.73	gold quality
adrenal cortex	UBERON:0001235	81.70	gold quality
pancreas	UBERON:0001264	81.67	gold quality
transverse colon	UBERON:0001157	81.63	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.71

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

62 targeting ZMYM6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-7154-5P	99.69	70.52	1900

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zmym6	ENSMUSG00000042408
rattus_norvegicus	Zmym6	ENSRNOG00000013865

Paralogs (18): GTF2IRD1 (ENSG00000006704), ZMYM2 (ENSG00000121741), ZMYM5 (ENSG00000132950), THAP12 (ENSG00000137492), ZMYM4 (ENSG00000146463), ZMYM3 (ENSG00000147130), KIAA1958 (ENSG00000165185), GTF2IRD2B (ENSG00000174428), EPM2AIP1 (ENSG00000178567), GTF2IRD2 (ENSG00000196275), ZMYM1 (ENSG00000197056), QRICH1 (ENSG00000198218), FAM200C (ENSG00000221886), FAM200A (ENSG00000221909), SCAND3 (ENSG00000232040), ZBED5 (ENSG00000236287), FAM200B (ENSG00000237765), GTF2I (ENSG00000263001)

Protein

Protein identifiers

Zinc finger MYM-type protein 6 — O95789 (reviewed: O95789)

Alternative names: Transposon-derived Buster2 transposase-like protein, Zinc finger protein 258

All UniProt accessions (2): O95789, X6RCN5

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in the regulation of cell morphology and cytoskeletal organization.

Subcellular location. Nucleus.

Tissue specificity. Expressed at high levels in heart, skeletal muscle, kidney and liver.

Isoforms (5)

UniProt ID	Names	Canonical?
O95789-3	3	yes
O95789-2	2
O95789-1	1
O95789-4	4
O95789-5	5

RefSeq proteins (1): NP_009098* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010507	Znf_MYM	Domain
IPR011017	TRASH_dom	Domain
IPR012337	RNaseH-like_sf	Homologous_superfamily
IPR051284	ZnF_MYMT-QRICH1	Family

Pfam: PF06467, PF24900

UniProt features (24 total): zinc finger region 8, splice variant 8, sequence variant 2, sequence conflict 2, chain 1, compositionally biased region 1, modified residue 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95789-F1	69.69	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 397

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 120 (showing top): GOBP_REGULATION_OF_CELL_MORPHOGENESIS, TGCGCANK_UNKNOWN, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, USF_C, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_CIS, chr1p34, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, ACEVEDO_LIVER_CANCER_UP, MODULE_207, BURTON_ADIPOGENESIS_11, IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM, USF2_Q6, MODULE_69

GO Biological Process (2): cytoskeleton organization (GO:0007010), regulation of cell morphogenesis (GO:0022604)

GO Molecular Function (4): DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
organelle organization	1
cell morphogenesis	1
regulation of anatomical structure morphogenesis	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

732 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZMYM6	ZNF841	Q6ZN19	561
ZMYM6	NECAB3	Q96P71	478
ZMYM6	CACHD1	Q5VU97	476
ZMYM6	ZNF354A	O60765	474
ZMYM6	AP4S1	Q9Y587	464
ZMYM6	TMEM35B	Q8NCS4	448
ZMYM6	RAB30	Q15771	437
ZMYM6	H3BQ15	H3BQ15	436
ZMYM6	AMDHD2	Q9Y303	432
ZMYM6	TEX13B	Q9BXU2	429
ZMYM6	TADA3	O75528	424
ZMYM6	ZNF436	Q9C0F3	422
ZMYM6	DMAP1	Q9NPF5	420
ZMYM6	SETDB2	Q96T68	418
ZMYM6	PSMB1	P20618	410

IntAct

104 interactions, top by confidence:

A	B	Type	Score
TAB1	MAP3K7	psi-mi:“MI:0914”(association)	0.900
GRB2	WIPF3	psi-mi:“MI:0914”(association)	0.730
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
QPRT	PIK3C2A	psi-mi:“MI:0914”(association)	0.640
SINHCAF	TNRC18	psi-mi:“MI:0914”(association)	0.640
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640
CDA	LIN7A	psi-mi:“MI:0914”(association)	0.640
ZNF707	ZNF316	psi-mi:“MI:0914”(association)	0.530
HAVCR2	TCAF2	psi-mi:“MI:0914”(association)	0.530
EMILIN1	METTL15	psi-mi:“MI:0914”(association)	0.530
ACOT12	INPPL1	psi-mi:“MI:0914”(association)	0.530
UCHL3	ZMYM6	psi-mi:“MI:0914”(association)	0.530
TIMP2	ZMYM6	psi-mi:“MI:0914”(association)	0.530
ZNF18	ZMYM6	psi-mi:“MI:0914”(association)	0.530
TUFM	ZMYM6	psi-mi:“MI:0914”(association)	0.530
CCDC89	ZMYM6	psi-mi:“MI:0914”(association)	0.530
FHL5	ZMYM6	psi-mi:“MI:0914”(association)	0.530

BioGRID (132): ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS), ZMYM6 (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8GR68, A2A791, B2GUN4, E1BP74, E1BZ85, F1QLG5, F7AQ22, O00472, O15164, O15550, O70546, O88974, O95789, P49140, P55265, P70365, Q14202, Q14596, Q15047, Q15788, Q4PJW2, Q5R413, Q5RC94, Q5RDJ2, Q5VZL5, Q64127, Q69Z66, Q6H8Q1, Q6KC51, Q6NXK2, Q6P3Y5, Q6PFK1, Q7Z3K3, Q8BJ34, Q8BL65, Q8BZH4, Q8CHY6, Q8IZD4, Q8TEW8, Q8VIG2

Diamond homologs: A2A791, A6QPH9, O95789, Q0P5J0, Q14202, Q2TAL8, Q3U2E2, Q3UA37, Q4R3D6, Q5RDJ2, Q5SVZ6, Q5VZL5, Q9CU65, Q9JLM4, Q9UBW7, Q9UJ78, A4Z943, A4Z944, A4Z945, P0CF97, Q49AG3, Q4R6P1, Q6R2W3, Q8IZ13, Q8TCP9, P17029, Q4KLI1, Q5R670, Q8BGS3, A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A2T6E3, A2T6V8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

170 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	125
Likely benign	17
Benign	14

Top pathogenic / likely-pathogenic (0)

SpliceAI

2872 predictions. Top by Δscore:

Variant	Effect	Δscore
1:34992229:CATA:C	donor_loss	1.0000
1:34992230:ATAC:A	donor_loss	1.0000
1:34992231:TA:T	donor_loss	1.0000
1:34992231:TACCT:T	donor_loss	1.0000
1:34992232:ACCT:A	donor_loss	1.0000
1:34992233:C:A	donor_loss	1.0000
1:34992233:CCTGT:C	donor_gain	1.0000
1:35003966:A:AC	donor_gain	1.0000
1:35003967:C:CC	donor_gain	1.0000
1:35003967:CAT:C	donor_gain	1.0000
1:35006945:TTTTA:T	donor_loss	1.0000
1:35006946:TTTA:T	donor_loss	1.0000
1:35006947:TTAC:T	donor_loss	1.0000
1:35006947:TTACC:T	donor_loss	1.0000
1:35006948:TACC:T	donor_loss	1.0000
1:35006949:A:AG	donor_loss	1.0000
1:35006949:A:T	donor_loss	1.0000
1:35006950:C:CG	donor_loss	1.0000
1:35006950:C:CT	donor_loss	1.0000
1:35007098:TCT:T	acceptor_loss	1.0000
1:35007099:C:CA	acceptor_loss	1.0000
1:35007099:C:CC	acceptor_gain	1.0000
1:35007100:T:A	acceptor_loss	1.0000
1:35008748:TTAC:T	donor_loss	1.0000
1:35008749:TA:T	donor_loss	1.0000
1:35008750:ACCTG:A	donor_loss	1.0000
1:35008751:C:CT	donor_loss	1.0000
1:35008783:CAAT:C	donor_gain	1.0000
1:35008920:GCAAA:G	acceptor_gain	1.0000
1:35008921:CAAA:C	acceptor_gain	1.0000

AlphaMissense

8734 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:35008797:A:C	F540L	0.999
1:35008797:A:T	F540L	0.999
1:35008799:A:G	F540L	0.999
1:35010525:A:G	C472R	0.998
1:35007089:A:G	C559R	0.997
1:35008798:A:G	F540S	0.997
1:35008865:A:G	C518R	0.997
1:35008922:A:G	C499R	0.997
1:35010523:A:C	C472W	0.997
1:35010524:C:G	C472S	0.997
1:35010525:A:T	C472S	0.997
1:35007088:C:G	C559S	0.996
1:35007089:A:T	C559S	0.996
1:35008854:A:C	C521W	0.996
1:35008856:A:G	C521R	0.996
1:35008863:G:C	C518W	0.996
1:35008920:G:C	C499W	0.996
1:35008921:C:G	C499S	0.996
1:35008922:A:T	C499S	0.996
1:35010456:A:G	C495R	0.996
1:35010515:C:G	C475S	0.996
1:35010516:A:T	C475S	0.996
1:35010524:C:T	C472Y	0.996
1:35008782:A:C	C545W	0.995
1:35008784:A:G	C545R	0.995
1:35008796:A:G	C541R	0.995
1:35008864:C:G	C518S	0.995
1:35008865:A:T	C518S	0.995
1:35008921:C:T	C499Y	0.995
1:35010454:A:C	C495W	0.995

dbSNP variants (sampled 300 via entrez): RS1000208212 (1:34986780 T>G), RS1000210656 (1:35033843 A>C), RS1000242619 (1:35016926 G>A), RS1000269768 (1:35007118 C>A,T), RS1000274000 (1:35030971 G>A,C), RS1000276884 (1:34986395 T>C), RS1000277956 (1:34996563 CAA>C), RS1000376889 (1:35000169 C>G), RS1000568286 (1:35030309 G>A,C,T), RS1000601854 (1:35010207 G>T), RS1000631710 (1:35018380 T>C,G), RS1000720938 (1:35030703 T>C), RS1000815710 (1:35005580 A>G), RS1000878339 (1:35005098 T>C), RS1000878385 (1:34998234 T>C)

Disease associations

OMIM: gene MIM:613567 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability	Limited	Autosomal dominant

Mondo (1): intellectual disability (MONDO:0001071)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004751_3	Serum uric acid levels in response to allopurinol in gout	4.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004761	uric acid measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, affects expression, decreases methylation, increases expression	6
trichostatin A	affects cotreatment, decreases expression, increases expression	3
Tretinoin	decreases expression, increases expression	2
Cyclosporine	increases expression	2
TAK-243	affects sumoylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	affects cotreatment, affects expression	1
arsenite	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	decreases expression	1
beta-methylcholine	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
AM 251	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, affects expression	1
belinostat	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression, affects expression	1
Decitabine	affects expression	1
Vorinostat	increases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Cisplatin	affects expression	1
Dexamethasone	affects cotreatment, affects expression	1
Formaldehyde	decreases expression	1
Indomethacin	affects cotreatment, affects expression	1
Methyl Methanesulfonate	increases expression	1
Quercetin	decreases expression	1
Testosterone	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, affects expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders